Finance

Lists
2607:HKG
Shanghai Pharmaceuticals Holding Co Ltd
11,18 HKD
+0,09%
(+0,010) 1D
20 ოქტ, 09:55:44 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2607...
Open
11,35 HKD
High
11,35 HKD
Low
11,17 HKD
Mkt. cap
64,66 მლრდ.
Avg. vol.
1,92 მლნ.
Volume
166,90 ათ.
Dividend
4,66%
Quarterly dividend
0,13 HKD
Ex-dividend date
18 სექ. 2026
P/E ratio
7,41
52-wk high
12,41 HKD
52-wk low
10,70 HKD
EPS
1,51 HKD
Shares outstanding
919,07 მლნ.
No. of employees
49 ათ.
Open
11,35 HKD
High
11,35 HKD
Low
11,17 HKD
Mkt. cap
64,66 მლრდ.
Avg. vol.
1,92 მლნ.
Volume
166,90 ათ.
Dividend
4,66%
Quarterly dividend
0,13 HKD
Ex-dividend date
18 სექ. 2026
P/E ratio
7,41
52-wk high
12,41 HKD
52-wk low
10,70 HKD
EPS
1,51 HKD
Shares outstanding
919,07 მლნ.
No. of employees
49 ათ.
News stories
From web sources and news partners
Profile
Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia
About Shanghai Pharmaceuticals Holding Co Ltd
CEO-
Employees48,6 ათ.
Founded18 იან. 1994
Headquarters-
SectorHealth care provider
Websitesphchina.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
73,48 მლრდ.
68,51 მლრდ.
75,26 მლრდ.
72,21 მლრდ.
Cost of goods sold
66,03 მლრდ.
60,55 მლრდ.
67,17 მლრდ.
64,09 მლრდ.
Cost of revenue
66,03 მლრდ.
60,55 მლრდ.
67,17 მლრდ.
64,09 მლრდ.
Research and development expenses
556,53 მლნ.
824,53 მლნ.
468,22 მლნ.
502,64 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,70 მლრდ.
4,97 მლრდ.
4,59 მლრდ.
4,65 მლრდ.
Operating expense
5,58 მლრდ.
5,91 მლრდ.
5,47 მლრდ.
5,55 მლრდ.
Total operating expenses
71,60 მლრდ.
66,47 მლრდ.
72,63 მლრდ.
69,64 მლრდ.
Operating income
1,88 მლრდ.
2,04 მლრდ.
2,63 მლრდ.
2,57 მლრდ.
Other non operating income
-84,84 მლნ.
-63,65 მლნ.
-47,88 მლნ.
-7,43 მლნ.
EBT including unusual items
1,48 მლრდ.
1,52 მლრდ.
2,42 მლრდ.
3,21 მლრდ.
EBT excluding unusual items
1,61 მლრდ.
1,44 მლრდ.
2,27 მლრდ.
3,03 მლრდ.
Income tax expense
485,91 მლნ.
534,14 მლნ.
569,09 მლნ.
720,64 მლნ.
Effective tax rate
32,89%
35,10%
23,52%
22,43%
Other operating expenses
129,62 მლნ.
271,29 მლნ.
132,16 მლნ.
186,62 მლნ.
Net income
688,20 მლნ.
577,49 მლნ.
1,42 მლრდ.
2,09 მლრდ.
Net profit margin
0,94%
0,84%
1,88%
2,89%
Earnings per share
-
-
-
-
Interest and investment income
206,57 მლნ.
-
38,70 მლნ.
873,52 მლნ.
Interest expense
-393,02 მლნ.
-470,36 მლნ.
-347,64 მლნ.
-358,39 მლნ.
Net interest expenses
-186,45 მლნ.
-470,36 მლნ.
-308,94 მლნ.
515,13 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
2,26 მლრდ.
2,54 მლრდ.
3,12 მლრდ.
3,07 მლრდ.
Gain or loss from assets sale
39,99 მლნ.
-157,15 მლნ.
-
-179,70 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები